|Bid||35.9400 x 2900|
|Ask||35.9500 x 1500|
|Day's Range||35.8800 - 36.1200|
|52 Week Range||29.8300 - 36.2100|
|PE Ratio (TTM)||26.29|
|Dividend & Yield||1.28 (3.61%)|
|1y Target Est||N/A|
Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.
Analysts estimate that Pfizer (PFE) stock has the potential to return ~5.9% over the next 12 months.
The Dow mopped up gains over the week, buoyed by announcements from the Federal Reserve.